Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UNIPROT:A9QXG9 (bcl-2)
 7,497 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Chromosome studies are helping to identify oncogenes, both known and previously unknown, involved in the pathogenesis of human lymphocytic tumors; and mechanisms by which the function of these genes is critically altered. Most extensively studied have been the chromosome translocations involving the myc gene in Burkitt's lymphomas and the bcl-2 gene in low-grade lymphomas, where "activation" of the oncogene results from association with a transcriptionally active immunoglobulin gene. Other putative oncogenes, similarly involved in translocations with immunoglobulin genes (in B-cell tumors) or T-cell receptor genes (in T-cell tumors), are currently being investigated, as well as alternative mechanisms of myc gene activation in these neoplasms. Limited clinical applications of these studies have already been forthcoming, and they should eventually lead to improvements in diagnosis, prognosis, and even therapy.
 ...
PMID:Philip Levine award lecture. Chromosome translocations and oncogenes in human lymphoid tumors. 219 79

Thirty-two extranodal lymphomas of the gastrointestinal (GI) tract underwent molecular genetic analysis by Southern blotting using probes for the immunoglobulin genes and the bcl-1, bcl-2, and c-myc loci, commonly involved in lymphomagenesis. No bcl-1 rearrangements were found. There was only one large-cell lymphoma with a bcl-2 rearrangement. A rearrangement of the c-myc gene was found in six of eight Burkittlike lymphomas of the intestine. In five of these six cases, a chromosomal translocation t(8;14) with an unusual breakpoint was demonstrated by comigration of the rearranged c-myc and a rearranged JH sequence. This pattern of rearrangement has not been previously associated with a specific group of non-Hodgkin's lymphomas. In contrast to all six low-grade lymphomas, c-myc rearrangements were found in 6 of 12 large-cell or high-grade mucosa-associated lymphomas of the stomach. No comigration of c-myc and immunoglobulin heavy-chain gene sequences were found. We conclude that primary GI lymphomas have different molecular genetic characteristics compared with node-based follicle center-cell lymphoma and as a group are not related to these lymphomas. In addition, the prevalence and patterns of c-myc rearrangements in the gastric large-cell lymphomas and ileocecal Burkittlike lymphomas are noteworthy and suggest a different and distinct pathogenesis for these tumors.
 ...
PMID:Molecular genetics of gastrointestinal non-Hodgkin's lymphomas: unusual prevalence and pattern of c-myc rearrangements in aggressive lymphomas. 220 May 38

Low-grade non-Hodgkin lymphomas (NHL) comprise a heterogeneous group of disorders both in terms of their cellular and histological composition as well as in terms of their clinical course. The most usually applied classification systems, the Working Formulation and the Kiel classification as well as the recently proposed Revised European American Lymphoma classification, discriminate between low-, intermediate- and high-grade subtypes. In general, low-grade NHL are characterized by a low to moderate proliferative activity and a long clinical course with median survival times ranging from approximately 3 years for centrocytic (CC) or mantle-cell lymphomas (MCL) to 5-8 years for centroblastic-centrocytic (CB-CC) or follicular lymphomas (FL). Recent cytogenetic and molecular biologic analyses indicate that these differences may result from distinct genetic abnormalities such as the translocation t(14;18), which is frequently observed in FL-NHL and is associated with a bcl-2 overexpression and inhibition of apoptosis, or the deregulation of PRAD1 in MCL-NHL induced by the translocation t(11;14). Therapy of low-grade lymphomas depends mainly on the extent of the disease. In the early stages I and II, at which approximately 15 to 20% of low-grade NHL are diagnosed, radiotherapy may be applied with curative intention. The treatment of patients with more advanced stages III and IV is controversial. The currently available information justifies a conservative approach of observing the natural course of the disease until therapeutic intervention is required due to the occurrence of B-symptoms, hematopoietic insufficiency or lymphoma progression.(ABSTRACT TRUNCATED AT 250 WORDS)
 ...
PMID:Current status and future perspectives in the treatment of low-grade non-Hodgkin's lymphomas. 788 29

Multinucleated giant cells resembling Reed-Sternberg (RS) cells are occasionally observed in high-grade lymphomas of the large-cell or immunoblastic type, but much less commonly in low-grade lymphomas. This study was conducted to determine whether RS-like cells found in seven B-cell low-grade lymphomas were immunologically similar to the neoplastic cells in the lymphoma or to the true RS cells seen in Hodgkin's disease, and whether they were therefore indicative of a composite lymphoma. Immunohistochemical studies were performed on paraffin sections of the seven low-grade (one small lymphocytic, one mantle zone, and five follicular) lymphomas with a panel of antibodies reactive with leukocyte common antigen (LCA), B-cell, T-cell, and Hodgkin's disease associated antigens. The RS-like cells were reactive with LCA (four of six), L26 (seven of seven), LN1 (five of six), LN2 (two of six), and MB2 (three of six). No positive staining was seen with either Leu-M1 or Ber-H2. The RS-like cells in the mantle zone lymphoma expressed L26, Leu-22, and kappa cytoplasmic light chains. This immunophenotype is similar to that of the neoplastic small lymphocytic cells. One of the low-grade follicular lymphomas progressed to an immunoblastic lymphoma with many RS-like cells. Paraffin immunohistochemistry on both lesions revealed a similar B-cell phenotype for the RS-like cells. Immunogenetic studies revealed B-cell and bcl-2 gene rearrangements in the immunoblastic lymphoma. These results indicate that RS-like cells in low-grade lymphomas are transformed neoplastic cells of B-cell lineage. With careful morphologic examination augmented by immunohistochemical studies, these lesions can be differentiated from Hodgkin's disease and from composite lymphomas of the combined Hodgkin's and non-Hodgkin's type.
 ...
PMID:Reed-Sternberg-like cells in low-grade lymphomas are transformed neoplastic cells of B-cell lineage. 832 99

Therapy for patients with low-grade lymphomas has never been standardized. Recently, new entities have been described which are included in the REAL classification, and whether these entities should be regarded as separate diseases is not yet clear. Regardless, three new developments in the management of patients with low-grade lymphomas deserve special attention for treatment programs in the future. First, it appears that patients with stage I, II, and III low-grade lymphomas may enjoy very prolonged disease-free intervals after treatment with combination chemotherapy and radiation therapy programs. Although investigators disagree on prognostic factors, new features, such as beta 2-microglobulin appear to predict results better than any other feature, and future studies should address this prognostic factor in assessing their results. Second, for patients with advanced stage disease, administration of interferon as maintenance therapy prolongs the disease-free interval, and use of this drug should be further investigated. Finally, molecular studies using PCR for bcl-2 may be clinically relevant in detecting residual disease in patients with follicular lymphomas, and future studies should focus on the value of eliminating the residual disease from blood and marrow.
 ...
PMID:Low-grade lymphomas: new entities and treatment concepts. 885 95

Inhibitors of programmed cell death (apoptosis) aberrantly prolonging cell viability may contribute to cancer by facilitating the insurgence of mutations and by promoting resistance to therapy. Despite the identification of several new apoptosis inhibitors related to bcl-2 or to the baculovirus IAP gene, it is not clear whether apoptosis inhibition plays a general role in neoplasia. Here, we describe a new human gene encoding a structurally unique IAP apoptosis inhibitor, designated survivin. Survivin contains a single baculovirus IAP repeat and lacks a carboxyl-terminal RING finger. Present during fetal development, survivin is undetectable in terminally differentiated adult tissues. However, survivin becomes prominently expressed in transformed cell lines and in all the most common human cancers of lung, colon, pancreas, prostate and breast, in vivo. Survivin is also found in approximately 50% of high-grade non-Hodgkin's lymphomas (centroblastic, immunoblastic), but not in low-grade lymphomas (lymphocytic). Recombinant expression of survivin counteracts apoptosis of B lymphocyte precursors deprived of interleukin 3 (IL-3). These findings suggest that apoptosis inhibition may be a general feature of neoplasia and identify survivin as a potential new target for apoptosis-based therapy in cancer and lymphoma.
 ...
PMID:A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma. 925 86

In this study we investigated the immunohistochemical expression of caspases 3, 6 and 8 in 85 malignant non-Hodgkin's lymphomas and in 4 hyperplastic lymph nodes. The extent of apoptosis and the immunohistochemical expression of bcl-2 and bax was also studied. Caspase 3 immunoreactivity was seen in 84/85 (99%), caspase 6 in 46/85 (54%), and caspase 8 in 66/85 (78%) lymphomas. The immunoreactivity for caspase 3 was diffuse cytoplasmic while antibodies to caspase 6 and 8 showed granular and fragmented, sometimes also nuclear immunopositivity. High-grade non-Hodgkin's lymphomas expressed strong caspase 6 and 8 immunoreactivity significantly more often than low-grade lymphomas (p = 0.016 and p = 0.0002, respectively). Strong caspase 3 immunoreactivity was also seen more often in high-grade lymphomas, but the association did not reach statistical significance (p = 0.14). There was a strong association between the expression of caspase 3 and 6 (p = 0.032), caspase 3 and 8 (p = 0.042), and especially between caspase 6 and 8 (p = <0.00001). There was a significant difference in the apoptotic index between low-grade (0.59+/-0.44%) and high-grade lymphomas (1.96+/-1.92%) (p<0.001). Strong bcl-2 expression was seen in 35/80 (44%) and strong bax expression in 20/80 (25%) lymphomas. No significant association was found between the expression of bcl-2 or bax and the expression of the caspases. According to the results the expression of caspases 6 and 8 is upregulated in high-grade compared with low-grade lymphomas and probably contributes to the execution of apoptosis in them. A similar tendency could also be seen with caspase 3. The expression of the three caspases is significantly associated, suggesting that it is mutually regulated. Finally, the results suggest that the expression of bcl-2 or bax does not influence the expression of caspases 3, 6 and 8 in malignant lymphomas to a significant degree.
 ...
PMID:Apoptosis and expression of caspases 3, 6 and 8 in malignant non-Hodgkin's lymphomas. 1059 77